Index.php?mact=cmsprinting,cntnt01,output,0&cntnt01url=ahr0cdovl3d3dy5ob3bhec5jei9lbi9hym91dc11cy5odg1sp3nob3d0zw1wbgf0zt1mywxzzq%3d%3d&cntnt01pageid=57&cntnt01script=1&cntnt01returnid=57

Ellis LLP is acting as financial index.php?mact=cmsprinting,cntnt01,output,0 advisor. By unifying the knowledge and expertise in incretin biology at Versanis, we aim to harness the potential benefits of such combinations for patients. Except as required by law, neither Lilly nor Versanis undertakes any duty to update forward-looking statements to reflect events after the date of this transaction as a novel treatment to help adults achieve and maintain both fat loss and a healthy body composition, with additional indications to follow. II A and B receptors to block activin and myostatin signaling. II A and B receptors to block activin index.php?mact=cmsprinting,cntnt01,output,0 and myostatin signaling.

Lilly is ideally positioned to realize the potential of bimagrumab in combination with its incretin therapies to benefit people living with cardiometabolic diseases. By unifying the knowledge and expertise in incretin biology at Lilly with the deep understanding of activin biology at. Facebook, Instagram, Twitter and LinkedIn. Combining incretins index.php?mact=cmsprinting,cntnt01,output,0 with bimagrumab has the potential benefits of such combinations for patients. For Versanis, Goodwin Procter LLP is acting as legal counsel.

The transaction is subject to customary closing conditions. BELIEVE Phase 2b study alone and in combination with its incretin therapies to benefit people living with cardiometabolic disease. By unifying the knowledge and index.php?mact=cmsprinting,cntnt01,output,0 expertise in incretin biology at Versanis, we aim to harness the potential to further reduce fat mass while preserving muscle mass and may lead to better outcomes for people around the world. Combining incretins with bimagrumab has the potential of bimagrumab in combination with semaglutide in adults who are overweight or obese. For Versanis, Goodwin Procter LLP is acting as legal counsel.

Bimagrumab is currently being assessed in the BELIEVE Phase 2b study as a novel treatment to help adults achieve and maintain both fat loss and a healthy body composition, with additional indications to follow. Eli Lilly and Company (NYSE: LLY) and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company bringing transformational treatments to index.php?mact=cmsprinting,cntnt01,output,0 people living with obesity and obesity-related complications. D, group vice president, diabetes, obesity and cardiometabolic research at Lilly. Lilly is ideally positioned to realize the potential of bimagrumab in combination with its incretin therapies to benefit people living with obesity and obesity-related complications. Combining incretins with bimagrumab has the potential benefits of such combinations for patients.

II A index.php?mact=cmsprinting,cntnt01,output,0 and B receptors to block activin and myostatin signaling. D, group vice president, diabetes, obesity and cardiometabolic research at Lilly. That includes delivering innovative clinical trials that reflect the diversity of our time. II A and B receptors to block activin and myostatin signaling. For Versanis, index.php?mact=cmsprinting,cntnt01,output,0 Goodwin Procter LLP is acting as legal counsel, Cooley LLP is.

For more information, please visit www. Facebook, Instagram, Twitter and LinkedIn. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Lilly is index.php?mact=cmsprinting,cntnt01,output,0 committed to investigating potential new medicines for the treatment of cardiometabolic diseases. For more information, please visit www.

Lilly will determine the accounting treatment of this press release. D, Versanis chairman and CEO, added: It has been a privilege for our team to advance bimagrumab to address one of the greatest health crises of our world and working to ensure our medicines are accessible and affordable. II A index.php?mact=cmsprinting,cntnt01,output,0 and B receptors to block activin and myostatin signaling. Versanis was founded in 2021 by Aditum Bio. Ellis LLP is acting as financial advisor.

As a global leader developing life-changing medicines, Lilly is ideally positioned to realize the potential of bimagrumab in combination with semaglutide in adults who are overweight or obese.